Aquestive Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aquestive Therapeutics has been growing earnings at an average annual rate of 15%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 4.3% per year.
Key information
15.0%
Earnings growth rate
30.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -4.3% |
Return on equity | n/a |
Net Margin | -15.6% |
Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics
May 26Revenue & Expenses BreakdownBeta
How Aquestive Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 51 | -8 | 32 | 13 |
30 Sep 23 | 48 | -12 | 34 | 14 |
30 Jun 23 | 47 | -23 | 39 | 15 |
31 Mar 23 | 47 | -33 | 47 | 16 |
31 Dec 22 | 48 | -54 | 53 | 17 |
30 Sep 22 | 48 | -71 | 56 | 18 |
30 Jun 22 | 50 | -73 | 56 | 19 |
31 Mar 22 | 52 | -69 | 53 | 18 |
31 Dec 21 | 51 | -71 | 53 | 17 |
30 Sep 21 | 47 | -62 | 54 | 17 |
30 Jun 21 | 42 | -64 | 54 | 20 |
31 Mar 21 | 48 | -54 | 55 | 19 |
31 Dec 20 | 46 | -56 | 56 | 20 |
30 Sep 20 | 55 | -48 | 57 | 19 |
30 Jun 20 | 59 | -50 | 59 | 16 |
31 Mar 20 | 49 | -68 | 61 | 21 |
31 Dec 19 | 53 | -66 | 64 | 21 |
30 Sep 19 | 53 | -68 | 67 | 23 |
30 Jun 19 | 54 | -64 | 65 | 23 |
31 Mar 19 | 57 | -80 | 83 | 23 |
31 Dec 18 | 67 | -61 | 72 | 23 |
30 Sep 18 | 63 | -61 | 61 | 24 |
30 Jun 18 | 77 | -38 | 55 | 25 |
31 Mar 18 | 74 | -8 | 27 | 22 |
31 Dec 17 | 67 | -14 | 25 | 22 |
31 Dec 16 | 52 | -12 | 21 | 15 |
Quality Earnings: AQST is currently unprofitable.
Growing Profit Margin: AQST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AQST is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare AQST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AQST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: AQST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.